Hepatocellular Carcinoma

A new drug application has been resubmitted to the FDA for the combination of camrelizumab and rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma, following a complete response letter in May 2024.

In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.

A combination of lenvatinib, pembrolizumab, and TACE significantly improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma compared to dual placebo and TACE.

The application is supported by the phase 3 CheckMate -9DW study, and the FDA has set a target action date of April 21, 2025.

During a Case-Based Roundtable® event, Pierre Gholam moderated a discussion on how to proceed with a patient presenting with a LI-RADS 5 mass suspected of being hepatocellular carcinoma.

The FDA has given positive feedback on the planned phase 3 study for the combination of amezalpat, atezolizumab, and bevacizumab in the first-line treatment of unresectable or metastatic hepatocellular carcinoma.